Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01030965 · ClinicalTrials.gov registry record · Phase 2
28-day Repeat Dose Study of GSK573719
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 285
- Enrollment target
NCT01030965 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 285 participants.
The verdict
NCT01030965, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 285 participants
- Enrollment target
Study Summary
The study will evaluate the efficacy, safety, and pharmacokinetics of GSK573719 compared with placebo in subjects with COPD
Interventions
- DRUG Placebo
- DRUG GSK573719 125mcg
- DRUG GSK573719 250mcg
- DRUG GSK573719 500mcg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 285 participants |
| Start Date | 2009-12-15 |
| Est. Completion | 2010-07-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01030965
The ClinicalTrials.gov registry entry for NCT01030965 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 285 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01030965 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01030965 about?
NCT01030965 is a clinical study titled "28-day Repeat Dose Study of GSK573719". The study will evaluate the efficacy, safety, and pharmacokinetics of GSK573719 compared with placebo in subjects with COPD
What is the current status of trial NCT01030965?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 285 participants. The study started on 2009-12-15. Estimated completion is 2010-07-04.
What interventions are being tested in trial NCT01030965?
The interventions under investigation include: Placebo (DRUG), GSK573719 125mcg (DRUG), GSK573719 250mcg (DRUG), GSK573719 500mcg (DRUG).
Who is sponsoring clinical trial NCT01030965?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.